Endocrine profile of a long-acting somatostatin derivative SMS 201–995. Study in normal volunteers following subcutaneous administration

Pozo, E. del; Neufeld, Michel; Schlüter, Kurt; Tortosa, Francisco; Clarenbach, P.; Bieder, E.; Wendel, Lucille P.; Nüesch, E.; Marbach, Peter; Cramer, H.; Kerp, L.

doi:10.1530/acta.0.1110433

Cited by 102 publications

(39 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a previous study, IGFBP-2 was found to be increased in many cancer patients (Kanety et al, 1993), and it is possible that the increase in this binding protein observed during tratment may be associated with disease progression rather than any influence of drug treatment. Somatostatin analogues are known to inhibit GH secretion (del Pozo et aL 1986). Surprisingly, we did not observe a consistent suppression of urinary GH in our patients.…”

Section: Statisticscontrasting

confidence: 79%

“…such effects could also be achieved through inhibition of growth factors and growth stimulatory hormones. Somatostatin analogues inhibit secretion of gastrointestinal hormones with possible mitogenic effects (Adrian et al 1981 ) and suppress synthesis of the insulin-like growth factor (IGF)-I (Pollak et al 1989: Figg et al 1995: Leo et al 1995 by suppressing growth hormone (GH) secretion (del Pozo et al 1986). the main trophic factor for IGF-I synthesis (Schwander et al 1983).…”

mentioning

confidence: 99%

See 1 more Smart Citation

Microencapsulated octreotide pamoate in advanced gastrointestinal and pancreatic cancer: a phase I study

et al. 1998

View full text Add to dashboard Cite

Summary Fourteen patients suffering from advanced colorectal (n = 7), pancreatic (n = 4) or gastric (n = 3) carcinomas received treatment with microencapsulated octreotide pamoate 90 mg i.m. every 4 weeks (n = 4), 160 mg i.m. every 4 weeks (n = 4) or 160 mg i.m. every 2 weeks (n = 6). Two patients had stable disease, one for 4 and one for 6 months. Plasma insulin-like growth factor (IGF)-I decreased by 49-53%, IGF-11 by 27-37% and total IGF-binding protein (IGFBP)-3 by 16-190/o, whereas IGFBP-1 increased by 35.55%. Insulin and Cpeptide levels decreased by 29-38% and 41-46% respectively. A non-significant decrease in urinary GH secretion and an increase in the ratio of fragmented to intact IGFBP-3 as well as IGFBP-3 protease activity was seen. The increase in IGFBP-3 fragmentation correlated negatively with alterations in IGF-I and IGF-II (P< 0.05). We conclude that microencapsulated octreotide administered in doses up to 160 mg every 2 weeks is well tolerated and has pronounced effects on several components of the IGF system in plasma. In addition, changes in IGFBP-3 protease actvity because of cancer may contribute to alterations in IGF-I and -Il, indicating the importance of measuring this parameter in addition to IGFs and IGFBPs when evaluating alterations in IGF-I.

show abstract

Section: Statisticscontrasting

confidence: 79%

mentioning

confidence: 99%

Microencapsulated octreotide pamoate in advanced gastrointestinal and pancreatic cancer: a phase I study

et al. 1998

View full text Add to dashboard Cite

show abstract

“…This concentration can be achieved clinicly after a subcutaneous injection of at least 200 pg of octreotide repeated every 8 h. (Del Pozo et al, 1988). On the contrary, octreotide was generally adminired at a dose of 200 pg twice daily or 100-150 pg thrice daily, this corresponds to 60-75% of the optimal dose as judged from pharmacokinetic models (Del Pozo et al, 1986;Dy et al, 1992).…”

Section: Resutmentioning

confidence: 99%

A randomised trial of octreotide vs best supportive care only in advanced gastrointestinal cancer patients refractory to chemotherapy

Cascinu¹,

Ferro²,

Catalano³

1995

Br J Cancer

View full text Add to dashboard Cite

Sry Octreotde, a somastain analoue, has been shown to inhibit the growth of strointestinal cancrs n vro and in vio. To al., 1982;Hudd et al., 1989;Townsend et al., 1989). The mehanism of action is not well known but is probably mediated by speific hormone receptors present in normal and tumour cells; thus there have been efforts to develop receptor antagonists as anti-cancer agents (Chang et al., 1986;Singh et al., 1986).One of the most important naturally occurring antiproliferative hormones is somatostatin. It has been shown to inhibit cellular proliferation in normal and neoplastic mucosa of stomach, pancreas and colon-rectum (Reichin, 1983).However, the short half-life of native somatostatin and the need for its intravenous administration makes long-term somatostatin therapy impactical (Sheppard et al., 1979).Octreotide, a synthetic somatostatin analogue, differs from natural somatostatin, which has a half-life of 1-3 in that it has higher potency and a much longer half-life (Bauer et al., 1982

show abstract

“…* Significantly different from baseline values. subjects and patients with insulinoma (Del Pozo et al, 1986;Johnston et al, 1986;Stehouwer et al, 1989). Octreotide suppressed plasma glucagon concentrations in the control dogs but not in the dogs with insulinoma.…”

Section: Discussionmentioning

confidence: 86%

“…However, spontaneous (nocturnal) GH peaks (in humans) and stimulated GH responses to clonidine and human Growth Hormone Releasing Hormone (hGHRH, in dogs) and arginine (in humans) are lowered by octreotide (Del Pozo et al, 1986;Johnston et al, 1986;Selman et al, 1991). In dogs with insulinoma, a more detailed study of the pulsatile pattern of GH secretion is necessary to elucidate the effect of octreotide on spontaneous pulsatile GH release (Kooistra et al, 2000).…”

Section: Discussionmentioning

confidence: 99%

Effect of octreotide on plasma concentrations of glucose, insulin, glucagon, growth hormone, and cortisol in healthy dogs and dogs with insulinoma

Robben

Brom

Mol

et al. 2006

Research in Veterinary Science

View full text Add to dashboard Cite

The inhibitory effect of the somatostatin analogue octreotide on the secretion of insulin could be used in the treatment of insulinoma. However, current information on the effectiveness of octreotide in dogs is conflicting. Therefore, the endocrine effects of a single subcutaneous dose of 50 lg octreotide were studied in healthy dogs in the fasting state (n = 7) and in dogs with insulinoma (n = 12).Octreotide did not cause any adverse effects. In healthy dogs in the fasting state, both plasma insulin and glucagon concentrations declined significantly. Basal (non-pulse related) GH and ACTH concentrations were not affected. A slight but significant decrease in the plasma glucose concentrations occurred.Dogs with insulinoma had significantly higher baseline insulin concentrations and lower baseline glucose concentrations than healthy dogs in the fasting state. Plasma glucagon, GH, ACTH, and cortisol concentrations did not differ from those in healthy dogs. Baseline plasma insulin concentrations decreased significantly in dogs with insulinoma after octreotide administration, whereas plasma concentrations of glucagon, GH, ACTH, and cortisol did not change. In contrast to the effects in the healthy dogs, in the dogs with insulinoma plasma glucose concentrations increased.Thus, the consistent suppression of plasma insulin concentrations in dogs with insulinoma, in the absence of an suppressive effect on counter-regulatory hormones, suggests that further studies on the effectiveness of slow-release preparations in the long-term medical treatment of dogs with insulinoma are warranted.

show abstract

Endocrine profile of a long-acting somatostatin derivative SMS 201–995. Study in normal volunteers following subcutaneous administration

Cited by 102 publications

References 12 publications

Microencapsulated octreotide pamoate in advanced gastrointestinal and pancreatic cancer: a phase I study

Microencapsulated octreotide pamoate in advanced gastrointestinal and pancreatic cancer: a phase I study

A randomised trial of octreotide vs best supportive care only in advanced gastrointestinal cancer patients refractory to chemotherapy

Effect of octreotide on plasma concentrations of glucose, insulin, glucagon, growth hormone, and cortisol in healthy dogs and dogs with insulinoma

Contact Info

Product

Resources

About